From January 13 to 16, 2020, Scandion Oncology will participate at the J.P. Morgan Healthcare Conference in San Francisco, USA. This annual conference, with more than 9,000 representatives from the pharmaceutical industry, the financial and service sectors and from academic institutions, is the largest of its kind in the world.
CEO Nils Brünner says: According to our new business strategy, we have initiated dialog with future potential partners of Scandion Oncology. The J.P Morgan Health Care Conference offers a unique opportunity for us meet relevant companies. Due to Peter Høngaard’s excellent business network, we have been able to arrange meetings with top executives both from large and medium sized pharma companies to present our technology. Our expectations are that we during these few days we could meet the future partner of Scandion Oncology.
For further information regarding Scandion Oncology, please contact:
Nils Brünner, CEO
Phone: +45 26 14 47 08
E-mail: nb@scandiononcology.com
Scandion Oncology A/S is a biotechnology company addressing and tackling one of the greatest challenges in modern oncology – the effective treatment of drug resistant cancers which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical in vitro-studies SCO-101 restores chemotherapy sensitivity in resistant cancer cells. Moreover, in animal studies, the company’s leading candidate drug, SCO-101, significantly enhances the efficacy of certain standard cancer treatments when given in combination. Scandion Oncology is now initiating clinical phase II trials with its lead compound, SCO-101 in patients with drug resistant cancer. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018.